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Summary
Identifying the cancer cells-of-origin is of great interest as it holds the potential to elucidate 
biological mechanisms inherent in the normal cell state that have been co-opted to drive the 
oncogenic cell state. An emerging concept, proposed here, states that cancer stem cells, key 
players in cancer initiation and metastasis, arise when transit-amplifying cells with mutant 
genomes dedifferentiate and enter the stem cell state. This model contrasts with the notion that 
cancer stem cells are the direct products of neoplastically transformed normal tissue stem cells.
The reigning models of how human tumors form describe a succession of changes in tumor 
cell genomes and in epigenomes (i.e., heritable changes in gene expression programs). Thus, 
a tiny subset of randomly occurring changes happens to confer advantageous cell 
phenotypes, resulting in the clonal expansion of the cells that express these phenotypes. 
Eventually the descendants of these cells will sustain yet another advantageous alteration, 
resulting once again in a clonal expansion. This process formally resembles the process of 
Darwinian evolution, with the proviso that it occurs in the microcosm of a tissue rather than 
in the wild. In the context of cancer, each of the clonal expansions generates a cell 
population with increased neoplastic phenotypes, culminating in the final, highly aggressive 
population that threatens the patient, both as a primary tumor and as the metastatic 
derivatives of this tumor(1).
Evidence is accumulating that both normal and fully neoplastic cell populations harbor 
subpopulations of stem cells (SCs) that can both self-renew and spawn more differentiated 
progeny. In the context of cancer, neoplastic SCs are proposed to hold most, if not all of the 
tumor-initiating potential. Moreover, a higher proportions of neoplastic SCs within a tumor 
often correlates with poorer prognosis. Experimentally, these functionally specialized cells 
can be defined through their ability to seed tumors following their initial implantation in 
appropriate host mice and subsequently during repeated cycles of serial passage in such 
hosts(2, 3).
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Given the presence of SCs in normal tissues prior to the onset of tumorigenesis and yet 
others within tumors formed at the final stages of multi-step tumor progression, it seems 
inevitable that all of the intermediate populations that arise successively, one after another, 
en route to full-fledged tumors also harbor such subpopulations. Of relevance here is the 
accumulating evidence that the SC programs in normal and neoplastic tissues rely on many 
common molecular regulators(4). Moreover, the organization of the normal SC hierarchy is 
also thought to apply to the cancer SC model, such that SC populations give rise to non-SC 
progeny, while the reverse process does not occur. i.e., non-SC progeny cannot 
dedifferentiate and re-enter the SC state.
Given the above, one reasonable model of how tumor progression proceeds depicts normal 
SCs as the initial targets of oncogenic transformation (5). Accordingly, a normal SC would 
sustain some type of heritable change, notably a genetic alteration, that generate a slightly 
altered SC; the latter would then spawn the larger cell population that is responsible for the 
altered behavior and histological phenotype of the resulting early, preneoplastic cell 
population. This process would then repeat itself, with each population of SCs sustaining a 
heritable change and directly generating the next successor population, until the final SC 
population arises, i.e., the cancer SCs present in a highly malignant tumor (Figure 1A).
This model is encumbered, however, by three inconsistencies that undermine its credibility. 
To begin, the rare stochastic changes that confer advantageous phenotypes are unlikely to 
occur if the population of potentially affected target cells is small; thus, small numbers of 
target cells yield proportionately small numbers of rare variants. Second, most types of 
heritable changes appear to occur far more frequently in actively dividing cell populations 
rather than in those that rarely divide; in general, it appears that epithelial SC populations 
divide far less frequently than their immediate progeny – the transit-amplifying/progenitor 
cells that are responsible for the exponential expansion of non-SC progeny and the lion’s 
share of mitotic activity in a tissue. Third, the clonal expansion of variant cell populations 
depends, as cited above, on the display of certain advantageous cell phenotypes; 
undifferentiated SCs are far less likely to display such phenotypes than their progeny that 
have initiated programs of differentiation. Taken together, these dynamics suggest that a 
model in which normal SCs are the cells-of-origin for epithelial cancers is mathematically 
and biologically implausible.
An alternative process seems to suggest a far more likely mechanistic model of multistep 
tumor progression. This emerging model is based upon recent findings in a number of 
laboratories that hierarchically organized cell populations are more plastic than previously 
imagined (6–10). Thus, depending on the genotype and the contextual signals experienced 
by transit-amplifying/progenitor cells, at least in epithelial tissues, such cells may 
dedifferentiate and thereby enter back into the SC pool. (The rates with which this occurs in 
various tissues in normal, neoplastic and physiologically stressed tissues, e.g., those 
undergoing wound healing, remain to be measured.)
This reversal of the arrow of differentiation makes possible a quite different scenario of how 
multi-step tumor progression actually occurs (Figure 1B). Thus, pools of transit-amplifying 
cells may serve as the actual targets of somatic alterations and thus the sources of mutant 
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genomes (or heritable epigenetic alterations) and thereafter feed these alterations back into 
corresponding SC pools. If so, this redirects our attention away from SCs as the key actors 
in the initiation and in the progression of human tumors, refocusing it on their mitotically far 
more active and more numerous transit-amplifying/progenitor progeny.
As an aside, we note that this alternative model holds important therapeutic implications: 
therapies aimed at targeting the cancer SCs within a tumor will not be curative if the pool of 
cancer SCs can be continuously regenerated from plastic non-cancer SCs that are capable of 
dedifferentiating and re-entering the cancer SC state. Moreover, this plastic model of 
tumorigenicity suggests that the pool of cells capable of successfully seeding a metastatic 
outgrowth is not restricted to the existing pool of cancer SCs within a primary tumor. 
Instead, the more differentiated progeny of these cancer SCs may also initiate metastases if 
they are capable of reverting to the tumor-initiating cancer SC state at distant sites of 
dissemination.
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Figure 1. 
The involvement of stem cells (SCs) in multi-step tumor progression can be depicted in two 
alternative mechanistic schemes. Both schemes embrace the notion that each participating 
cell population beginning with fully normal cells and culminating in fully neoplastic cells 
contains a subpopulation of SCs. (A) In this scheme, one SC subpopulation, having acquired 
a heritable change such as a somatic mutation, evolves directly into the next SC 
subpopulation with no involvement of non-SCs in this multi-step process. (B) An alternative 
scheme proposes that the heritable changes in cell populations are initially acquired in non-
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SC populations, specifically transit-amplifying cells, often termed progenitor cells. Having 
acquired an advantageous change, progenitor cells introduce this change into a SC 
subpopulation via a process of dedifferentiation. Accordingly, SCs change progressively 
during multi-step tumor progression but are not themselves the initial sources of these 
changes.
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